Radiosynthesis and validation of [5-cyano-N-(4-(4-[11C]methylpiperazin-1-yl)-2-(piperidin-1-yl)phenyl) furan-2-carboxamide] ([11C]CPPC), a PET radiotracer for imaging CSF1R, a microglia-specific marker

Research output: Contribution to journalArticle

Abstract

In this practitioner protocol, the radiochemical synthesis of [11C]CPPC is described in detail, and a quality control summary of three validation productions is presented. The results indicate that the radiotracer product can be produced in good radiochemical yield (> 60 mCi (2.22 GBq) at end-of-synthesis (EOS)), at high specific activity (molar activity > 11,435 mCi/μmole (423 GBq/μmole) at EOS) and high chemical and radiochemical purity. The entire production conforms to current Good Manufacturing Practice (cGMP) requirements. The final product is formulated as a sterile, pyrogen-free solution suitable for human injection.

Original languageEnglish (US)
Pages (from-to)903-908
Number of pages6
JournalJournal of Labelled Compounds and Radiopharmaceuticals
Volume62
Issue number13
DOIs
StatePublished - Nov 1 2019

    Fingerprint

Keywords

  • CPPC
  • CSF1R
  • PET
  • QC
  • synthesis

ASJC Scopus subject areas

  • Analytical Chemistry
  • Biochemistry
  • Radiology Nuclear Medicine and imaging
  • Drug Discovery
  • Spectroscopy
  • Organic Chemistry

Cite this